Pfizer's Q1 Earnings Drop: Is the 6.7% Dividend Safe?

Pfizer recently reported its first-quarter results for 2026, presenting a mixed financial picture. While the company's revenue grew by 5% year-over-year, its bottom line told a different story. Net income fell by 9%, and on an adjusted basis, the decline was even steeper at 18%.

The core issue for dividend-focused investors lies in two key metrics: earnings per share (EPS) and free cash flow. Pfizer's EPS for the quarter was $0.47, which is only slightly above its quarterly dividend payment of $0.43.

This narrow margin results in a payout ratio exceeding 91%, meaning the company is paying out almost all of its profits to shareholders. The situation looks worse when examining cash flow, as quarterly free cash flow of $2.2 billion fell short of the $2.4 billion needed to cover the dividend.

Despite these concerning figures, company management has publicly reaffirmed its commitment to the current dividend, offering no immediate signal of a cut. The earnings decline comes amid a period where Pfizer has been actively pursuing acquisitions and integrating past deals.

For income investors drawn to Pfizer's massive 6.7% yield, this earnings report is a crucial stress test. A dividend is only as safe as the company's ability to generate the cash to pay it. A payout ratio consistently above 90% leaves almost no buffer for unexpected setbacks, making the dividend vulnerable to any further earnings pressure.

The negative free cash flow coverage is arguably more alarming than the high payout ratio. Earnings can be influenced by accounting rules, but cash is the literal fuel for dividend payments. If a company's operational cash generation can't cover its shareholder payouts, it may need to borrow money or sell assets to fund the dividend—a strategy that is not sustainable long-term.

This puts Pfizer at a crossroads. The company must prove it can improve profitability through cost-cutting and synergies from its recent acquisitions. If it succeeds, the dividend could stabilize. If not, the math may force management's hand.

The outcome has broad implications. A dividend cut would likely cause a sharp decline in Pfizer's stock price, as income-focused investors sell their shares. Conversely, if Pfizer can navigate this period and maintain the payout, it could solidify its reputation as a reliable income stock, albeit one with higher risk.